Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study

Study of 282 dolutegravir and 148 efavirenz regimens found fewer people discontinued dolutegravir due to adverse effects (12.1% vs 35.8%, p<0.001). Patients with psychiatric disorders were at higher risk of discontinuation due to neuropsychiatric adverse events.

European Journal of Hospital Pharmacy